Swiss Biotech Association reports CHF 7.5 billion revenue for Switzerland’s biotech Industry in 2025

The private funding rose 38% amid growing international collaborations and CDMO demand

Japanese pharma firms turn to CDMOs early as peptide complexity rises

Neuland Laboratories reported an uptick in peptide-related engagements from Japanese companies, particularly at the preclinical and early clinical stages

Neuland Laboratories elevates Saradhi Bolli to Global Head of CDMO Business Development

Bolli will lead worldwide business development for the company’s Contract Development and Manufacturing Organisation (CDMO) services

Cambrex advances $120M US API expansion with Charles City Engineering milestone

The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026

LGM Pharma commits $15M to US facilities in major CDMO expansion

This follows a $6 million expansion in Rosenberg in 2025 and signals a major push to boost commercial capacity, expand R&D capabilities, and meet rising demand for US-based drug product manufacturing

Catalent and S.Biomedics join forces to advance groundbreaking Parkinson’s therapy

TED?A9 is part of S.Biomedics’ expanding pipeline of stem-cell-based therapies, developed using the company’s proprietary targeted embryonic stem cell differentiation platform

Sai Life Sciences posts stellar Q3, revenue surges 27% YoY; PAT nearly doubles

Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26

VectorBuilder Redefines Plasmid Standards with miniVec

Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively

Navin Fluorine inaugurates Phase-1 of new cGMP-4 facility of Navin Molecular at Devas

The cGMP-4 facility will further strengthen the company's ability to serve global partners

Lupin achieves GMP certification from TGA Australia for Dabhasa API facility